海创药业：氘恩扎鲁胺软胶囊纳入2025年国家医保药品目录

Core Viewpoint - Haichuang Pharmaceutical announced that its self-developed drug, Deutetrabenazine soft capsules (brand name: Hainan'an®), has been included in the National Medical Insurance Directory for 2025, effective from January 1, 2026, with an agreement valid until December 31, 2027 [1] Group 1 - The drug is a first-class new medication for the treatment of metastatic castration-resistant prostate cancer, demonstrating excellent safety [1] - Inclusion in the medical insurance directory will facilitate market promotion and reduce the financial burden on patients [1] - The company will actively promote the implementation of the medical insurance policy [1]